Pharmacosmos

Executive Summary

Pharmacosmos is a Danish, family-held pharmaceutical company founded in 1965 that has established itself as a global leader in carbohydrate chemistry and the treatment of iron deficiency and iron deficiency anemia. The company is fully integrated, covering research, development, manufacturing, and commercialization, with its products marketed in over 80 countries. Known for its pioneering work in iron carbohydrate complexes, Pharmacosmos has developed a strong portfolio of intravenous iron therapies, including Monofer (iron isomaltoside 1000), which is used to treat iron deficiency in various patient populations. The company's private ownership allows it to focus on long-term innovation and quality, rather than short-term shareholder returns. With a broad international footprint and a commitment to addressing unmet medical needs in iron management, Pharmacosmos continues to expand its global presence and therapeutic applications.

Upcoming Catalysts (preview)

• Q4 2026Potential FDA approval for Monofer in the U.S. for new indications or expanded labeling65% success
• Q1 2027Expansion of commercial presence in emerging markets through new partnerships or distribution agreements75% success
• Q3 2026Positive Phase 3 data for a novel iron formulation targeting specific patient populations (e.g., chronic kidney disease or heart failure)60% success